ZyCoV-D COVID-19 Vaccine Description
ZyCoV-D is "India's first indigenously developed DNA vaccine candidate against Covid-19. The ZyCoV-D vaccine candidate is being developed by Zydus Cadila and has been approved by Drugs Controller General of India (DCGI) for the conduct of a Phase III clinical trial," the Department of BioteBiotechnology said.
ZyCov-D is being developed on a DNA platform using a non-replicating and non-integrating plasmid carrying the novel coronavirus gene, making it very safe. The DNA platform is known to have better vaccine stability and lower cold chain requirements, which would make it easier to store and transport to remote parts of the country.
The vaccine candidate has been supported by the National Biopharma Mission (NBM) under the Biotechnology Industry Research Assistance Council (BIRAC), a PSU under the DBT.
Zydus Cadila is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim in India and the USA, and Brazil.
ZyCoV-D COVID-19 Vaccine Indication
ZyCoV-D COVID-19 Vaccine candidate is indicated to prevent COVID-19, the disease caused by the SARS-CoV-2 virus.
ZyCoV-D COVID-19 Vaccine News
January 3, 2021 - Zydus Cadila announced that it would be starting Phase III clinical trials of its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D after receiving permissions from the DCGI. Speaking on the development, Mr. Pankaj R. Patel, Chairman of the Zydus Group, said, “We are reaching a critical milestone in our vaccine development program and towards our goal of helping people fight the pandemic with an indigenously discovered, safe and efficacious vaccine. The launch of the Phase 3 trial will determine the efficacy of our vaccine in preventing COVID-19 which continues to pose a major threat, the world over.”
December 24, 2020 - Zydus Cadila announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D, was found to be safe, well-tolerated, and immunogenic in the Phase I/II clinical trials. The company is now planning to initiate Phase III clinical trials in around 30,000 volunteers upon receiving necessary approvals.
July 9, 2020 - COVID-19 Vaccine Development Update.
ZyCoV-D COVID-19 Vaccine Clinical Trials
Phase II study of ZyCoV-D had been conducted in over 1000 healthy adult volunteers as part of the adaptive Phase I/II dose-escalation, multi-centric, randomized, double-blind placebo-controlled study.
A phase III study has been approved and will commence shortly.